Eventide Healthcare & Life Sciences Fund CLASS N SHARES (ETNHX)

31.11
Net Asset Value
-0.73%
1 Day
+8.51%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
No Load
Sales Expenses
1.55%
Expense Ratio
High
Morningstar Risk Rating™
Investment Objective The investment seeks to provide long-term capital appreciation. Under normal market conditions- the fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in equity and equity-related securities of companies in the healthcare and life sciences sectors- including common stock- options- preferred stock and convertible debt. It may invest without limitation in securities of companies domiciled outside the United States either directly or through American Depositary Receipts ("ADRs"). The fund may invest in securities of companies of any market capitalization.

Performance

1 month+0.22% 3 years+9.07%
3 months+4.57% 5 years+21.71%
1 year+43.85% Since inception+23.87%
Data through --

Peer Comparisonvs. Health

 ETNHXCategory
Performance 5-yr return+21.71%+14.29%
Expense ratio1.55%1.30%
Risk 5 year sharpe ratio0.830.92
Net assets$535.6M$3.0B
Average market cap$2.0B$10.0B
Average P/E--22.2
Portfolio turnover27%27%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyEventide Funds
Fund manager & tenureFinny Kuruvilla / 5 Years
Minimal initial investment$1,000.00
Minimum IRA investment$1,000.00

Holdings

U.S. stock78.53%
International stock13.65%
Cash7.67%
Fixed income0.14%
Other0.00%
Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
SAGE SAGE Therapeutics Inc3.49%
COLL Collegium Pharmaceutical Inc3.48%
AIMT Aimmune Therapeutics Inc3.00%
ASND Ascendis Pharma A/S2.94%
AVXS AveXis Inc2.90%
BLUE bluebird bio Inc2.69%
NBIX Neurocrine Biosciences Inc2.65%
VYGR Voyager Therapeutics Inc2.55%
ALNY Alnylam Pharmaceuticals Inc2.50%
BPMC Blueprint Medicines Corp2.47%